Company: SCLXW
Filing Date: 2025-12-29
Form Type: 424B3
Source: 0001193125-25-335429
Chunk: 637

Company: Scilex Holding Co
Filing Date: 2025-12-29
Form: 424B3
Chunk 637
---
pecified therein to among other things, research, develop, make, have made, use, sell, have sold, offer for sale, import, export, register, market, promote, advertise, commercialize and distribute the Proprietary Materials (as defined in the Datavault License Agreement, including a suite of patents related to Datavault’s data platforms and any products created therefrom within the Target Market (as defined below). F-106

With respect to the foregoing, “Target Market” shall mean industries including biotechnology,
biopharmaceutical, genetic, diagnostic, and data-related industries, and any markets relating to the generation, use, storage, analysis, tokenization, and exchange of DNA, genetic, diagnostic, and therapeutic data or materials.

The Datavault License Agreement expires upon the expiry of the patents underlying the Proprietary Materials, at which point the license shall become
perpetual, irrevocable, non-exclusive and royalty-free. The Datavault License Agreement is subject to earlier termination if, among other things: (i) either party ceases to exist or becomes insolvent,
(ii) either party commits a material breach of the Datavault License Agreement, (iii) the Company fails to make any required payment to Datavault that is not cured within 15 days, or (iv) the Company does not achieve and maintain
annual royalty payments to Datavault of a minimum of $1,000,000 after 24 months following the date of the Datavault License Agreement.

As consideration
for the license under the Datavault License Agreement, the Company agreed to pay Datavault (a) a non-refundable license fee of $10,000,000, payable in four equal installments of $2,500,000 on or before
the last day of each fiscal quarter, beginning on December 31, 2025, (b) subject to achievement of certain net sales for the Licensed Product (as defined therein), up to an aggregate of $2,550,000,000, and (c) a five-percent (5%) royalty
on net sales of the Product (as defined therein) during the applicable royalty term under the Datavault License Agreement.

The Datavault License
Agreement contains customary reciprocal indemnification obligations for Datavault and the Company and customary representations and warranties.

Sale of Datavault Shares

Subsequent to
September 30, 2025, the Company sold 10,224,112 shares